CommercialPrior AuthMedium impact
Axatilimab-csfr (Niktimvo) (CPB 1069, reviewed 2026-05-27)
Aetna·Oncology, Hematology, Internal Medicine +1 more·Medical Policy
Effective date
May 27, 2026
We identified it
Aug 12, 2026
Summary
Aetna has established coverage for axatilimab-csfr (Niktimvo) for chronic graft-versus-host disease (cGVHD) in commercial plans, effective immediately. This newly FDA-approved medication requires precertification before administration and is only covered after failure of at least two prior systemic therapies in patients weighing ≥40 kg. Billing teams must implement prior authorization requirements and ensure proper coding for this specialty pharmaceutical.
Action Required
IMMEDIATE: Billing team must implement precertification requirement for all axatilimab-csfr (Niktimvo) claims. (1) Update billing system to flag claims with HCPCS J9038 for mandatory prior authorization before processing. (2) Providers must obtain precertification by calling (866) 752-7021 or faxing (888) 267-3277 before administering the drug. (3) Submit Statement of Medical Necessity (SMN) precertification forms (available through Specialty Pharmacy Precertification portal). (4) Verify patient eligibility criteria in system: ≥2 prior lines of systemic therapy for cGVHD AND patient weight ≥40 kg. (5) Update encounter templates to require documentation of prior treatment failures and patient weight. (6) Bundle chemotherapy administration codes 96413 and 96415 with J9038 for accurate infusion time billing. Failure to obtain precertification will result in claim denials. Flag any requests for off-label indications as experimental/investigational and refer to Medicare Part B criteria for Medicare beneficiaries.